WO2014103801A1 - イミダゾピリジン誘導体を有効成分として含むoct3活性阻害剤又はoct3検出剤 - Google Patents
イミダゾピリジン誘導体を有効成分として含むoct3活性阻害剤又はoct3検出剤 Download PDFInfo
- Publication number
- WO2014103801A1 WO2014103801A1 PCT/JP2013/083759 JP2013083759W WO2014103801A1 WO 2014103801 A1 WO2014103801 A1 WO 2014103801A1 JP 2013083759 W JP2013083759 W JP 2013083759W WO 2014103801 A1 WO2014103801 A1 WO 2014103801A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituent
- formula
- oct3
- alkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 63
- 239000003795 chemical substances by application Substances 0.000 title claims description 15
- 238000001514 detection method Methods 0.000 title claims description 10
- 230000000694 effects Effects 0.000 title abstract description 22
- 101150086694 SLC22A3 gene Proteins 0.000 title 1
- 125000004857 imidazopyridinyl group Chemical class N1C(=NC2=C1C=CC=N2)* 0.000 title 1
- 101710102693 Solute carrier family 22 member 3 Proteins 0.000 claims abstract description 138
- 102100036929 Solute carrier family 22 member 3 Human genes 0.000 claims abstract description 138
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000012453 solvate Substances 0.000 claims abstract description 8
- -1 pyrrolidinyl (pyrrolidinyl) group Chemical group 0.000 claims description 203
- 125000001424 substituent group Chemical group 0.000 claims description 164
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 56
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 31
- 125000000304 alkynyl group Chemical group 0.000 claims description 31
- 125000004414 alkyl thio group Chemical group 0.000 claims description 29
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 9
- 108091006764 Organic cation transporters Proteins 0.000 claims description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000025748 atypical depressive disease Diseases 0.000 claims description 2
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 230000002085 persistent effect Effects 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 208000012672 seasonal affective disease Diseases 0.000 claims description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 2
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 125000003046 allene group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 description 63
- 238000012360 testing method Methods 0.000 description 38
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 27
- 125000003277 amino group Chemical group 0.000 description 26
- 238000000034 method Methods 0.000 description 22
- 239000000935 antidepressant agent Substances 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 19
- 230000001430 anti-depressive effect Effects 0.000 description 18
- 229940005513 antidepressants Drugs 0.000 description 18
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 16
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 16
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- 230000009182 swimming Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000009471 action Effects 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000006742 locomotor activity Effects 0.000 description 11
- 239000007995 HEPES buffer Substances 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000008515 histamine uptake Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 210000003722 extracellular fluid Anatomy 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- 150000005232 imidazopyridines Chemical class 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 7
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 7
- 229960001252 methamphetamine Drugs 0.000 description 7
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 5
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 5
- 229960001596 famotidine Drugs 0.000 description 5
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 5
- 229960004801 imipramine Drugs 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940126585 therapeutic drug Drugs 0.000 description 4
- 210000000211 third ventricle Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101150025224 OCT3 gene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 239000000823 artificial membrane Substances 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 2
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091006735 SLC22A2 Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100032417 Solute carrier family 22 member 2 Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- JRTIDHTUMYMPRU-UHFFFAOYSA-N alpidem Chemical compound N1=C2C=CC(Cl)=CN2C(CC(=O)N(CCC)CCC)=C1C1=CC=C(Cl)C=C1 JRTIDHTUMYMPRU-UHFFFAOYSA-N 0.000 description 2
- 229950008673 alpidem Drugs 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JPAWFIIYTJQOKW-UHFFFAOYSA-N olprinone Chemical compound N1C(=O)C(C#N)=CC(C2=CN3C=CN=C3C=C2)=C1C JPAWFIIYTJQOKW-UHFFFAOYSA-N 0.000 description 2
- 229950005421 olprinone Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
- 125000006028 1-methyl-2-butenyl group Chemical group 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006031 2-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- LIHAMTVZVPKWIL-UHFFFAOYSA-N CC(C)(CC1)C=[S]1(=O)=O Chemical compound CC(C)(CC1)C=[S]1(=O)=O LIHAMTVZVPKWIL-UHFFFAOYSA-N 0.000 description 1
- KZNOGTSWLDQYBV-UHFFFAOYSA-N CC(C)(CC1)CS1(=O)=O Chemical compound CC(C)(CC1)CS1(=O)=O KZNOGTSWLDQYBV-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- VKEBWCZVWZDPKV-UHFFFAOYSA-N Cc1ccc(C2SCCS2)cc1 Chemical compound Cc1ccc(C2SCCS2)cc1 VKEBWCZVWZDPKV-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 1
- 102100036908 Equilibrative nucleoside transporter 4 Human genes 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940122498 Gene expression inhibitor Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 101100094863 Homo sapiens SLC29A4 gene Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101100094847 Mus musculus Slc22a3 gene Proteins 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007052 brain toxicity Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 231100000976 cerebrotoxicity Toxicity 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000006627 ethoxycarbonylamino group Chemical group 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000006631 isobutoxycarbonylamino group Chemical group 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000006626 methoxycarbonylamino group Chemical group 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006126 n-butyl sulfonyl group Chemical group 0.000 description 1
- 125000002004 n-butylamino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006257 n-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])OC(*)=O 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004888 n-propyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006124 n-propyl sulfonyl group Chemical group 0.000 description 1
- 125000006256 n-propyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC(*)=O 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 230000005944 tissue migration Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- VSLIUWLPFRVCDL-UHFFFAOYSA-N zolimidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 VSLIUWLPFRVCDL-UHFFFAOYSA-N 0.000 description 1
- 229960003118 zolimidine Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to an organic cation transporter 3 (OCT3) activity inhibitor and an OCT3 detector comprising an imidazopyridine derivative as an active ingredient.
- OCT3 organic cation transporter 3
- OCT organic cation transporter
- OCT3 exists not only in the placenta but also in the kidney, small intestine, lung, heart, and brain.
- Nucleoside derivatives, quinoline derivatives, and tricyclic compounds have been reported as OCT3 activity inhibitors, but these are difficult to use as drugs because of problems such as side effects. Moreover, a guanidine derivative has been reported as an OCT3 activity inhibitor (Non-patent Document 1 below).
- IC 50 of famotidine and cimetidine is a 20 ⁇ M and 240 ⁇ M respectively
- IC 50 of ramosetron and granisetron (Setoron compounds) are both reported below and 100 [mu] M.
- Patent Document 1 discloses a psychiatric remedy containing an organic cation transporter OCT3 gene expression inhibitor as an active ingredient.
- Patent Document 2 discloses a therapeutic drug for depression by inhibiting the function of OCT3, including an antisense nucleic acid of the OCT3 gene.
- Patent Document 3 discloses a therapeutic drug for depression by inhibiting the function of OCT3, which contains alkylamine-catechol derivatives, quinoline derivatives and bis-quinoline derivatives as active ingredients. .
- Patent Document 4 discloses a therapeutic drug for depression and depression-like symptoms containing famotidine as an active ingredient.
- US Pat. No. 6,403,645 discloses a therapeutic agent for depression containing an inhibitor of transporter Uptake 2 (OCT and PMAT) as an active ingredient.
- Zolpidem is a therapeutic agent for insomnia that acts on the ⁇ 1-type GABA A receptor.
- Alpidem is an anxiolytic agent that acts on peripheral benzodiazepine receptors.
- Zolimidin is an anti-ulcer agent.
- Olprinone is a therapeutic agent for acute heart failure having PDE3 inhibitory action.
- an object of the present invention is to provide an OCT3 activity inhibitor having a different basic skeleton from conventional OCT3 activity inhibitors.
- Another object of the present invention is to provide a therapeutic agent for diseases involving OCT3.
- an object of the present invention is to provide a detection agent for OCT3.
- the present invention is basically based on the knowledge that imidazopyridine derivatives (particularly imidazo [1,2-a] pyridine derivatives) have the ability to bind to OCT3 and to inhibit OCT3 activity.
- the first aspect of the present invention is an organic cation transporter 3 (comprising a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof as an active ingredient). It relates to inhibitors of OCT3).
- R 1 to R 3 and R 5 to R 6 may be the same or different, A hydrogen atom, a halogen atom, a C 1-3 alkyl group, a C 1-3 alkoxy group, a C 1-3 alkylthio group, or a C 1-3 halogenoalkyl group;
- R 4 represents any group of formula (II) to formula (VII).
- X 2 represents a C 1-10 alkyl group which may have a substituent, a C 1-10 alkoxy group which may have a substituent, a C 1-10 alkylthio group which may have a substituent, a substituent A C 2-10 alkenyl group which may have a group or a C 2-10 alkynyl group which may have a substituent;
- X 3 is a C 1-10 alkyl group which may have a substituent, a C 1-10 alkoxy group which may have a substituent, a C 1-10 alkylthio group which may have a substituent, a substituent A C 2-10 alkenyl group which may have a group or a C 2-10 alkynyl group which may have a substituent;
- a symbol (*) was given to the bond portion with the carbon atom (C) adjacent to R 4 .
- X 4 is a C 1-10 alkyl group which may have a substituent, a C 1-10 alkoxy group which may have a substituent, a C 1-10 alkylthio group which may have a substituent, a substituent A C 2-10 alkenyl group which may have a group, a C 2-10 alkynyl group which may have a substituent, or a C 6-12 aryl group which may have a substituent.
- X 5 is a C 1-10 alkyl group which may have a substituent, a C 1-10 alkoxy group which may have a substituent, a C 1-10 alkylthio group which may have a substituent, a substituent
- a C 2-10 alkenyl group which may have a group, a C 2-10 alkynyl group which may have a substituent, a 5-membered ring group which may have a substituent or a substituent C represents a 6-12 aryl group.
- X 6 represents a C 1-10 alkyl group which may have a substituent, a C 1-10 alkoxy group which may have a substituent, a C 1-10 alkylthio group which may have a substituent, a substituent
- a C 2-10 alkenyl group which may have a group, a C 2-10 alkynyl group which may have a substituent, a 5-membered ring group which may have a substituent or a substituent C represents a 6-12 aryl group.
- X 7 represents a C 1-10 alkyl group which may have a substituent, a C 1-10 alkoxy group which may have a substituent, a C 1-10 alkylthio group which may have a substituent, a substituent
- a C 2-10 alkenyl group which may have a group, a C 2-10 alkynyl group which may have a substituent, a 5-membered ring group which may have a substituent or a substituent C represents a 6-12 aryl group.
- the second aspect of the present invention relates to a therapeutic agent for mental illness containing any of the above-mentioned “inhibitors of organic cation transporter 3 (OCT3)” as an active ingredient. More specifically, this aspect relates to a therapeutic agent for depression comprising an inhibitor of any of the organic cation transporter 3 (OCT3) described above as an active ingredient.
- OCT3 organic cation transporter 3
- the third aspect of the present invention relates to a detection agent for organic cation transporter 3 (OCT3).
- an OCT3 activity inhibitor having a different basic skeleton from the conventionally known OCT3 activity inhibitors can be provided.
- the present invention can provide a therapeutic agent for diseases involving OCT3.
- the present invention can provide a detection agent for OCT3.
- the first aspect of the present invention comprises a compound represented by the formula (I) (the compound of the present invention), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof as an active ingredient.
- the present invention relates to an inhibitor of organic cation transporter 3 (OCT3).
- OCT3 organic cation transporter 3
- the compound of the present invention is an imidazopyridine derivative. More specifically, the compound of the present invention is an imidazo [1,2-a] pyridine derivative.
- R 1 to R 3 and R 5 to R 6 may be the same or different and are a hydrogen atom, a halogen atom, a C 1-3 alkyl group, a C 1-3 alkoxy group, a C 1-3 alkylthio group, or C 1 -3 represents a halogenoalkyl group.
- Preferred examples of R 1 to R 3 and R 5 to R 6 are a hydrogen atom or a C 1-3 alkyl group.
- the C 1-3 alkyl group is preferably a methyl group or an ethyl group.
- R 4 represents any group of formulas (II) to (VII).
- X 2 represents a C 1-10 alkyl group which may have a substituent, a C 1-10 alkoxy group which may have a substituent, a C 1-10 alkylthio group which may have a substituent, a substituent A C 2-10 alkenyl group which may have a group, a C 2-10 alkynyl group which may have a substituent, a C 6-10 aryl group which may have a substituent, or a substituent An optionally substituted C 7-10 aralkyl group is shown.
- X 3 is a C 1-10 alkyl group which may have a substituent, a C 1-10 alkoxy group which may have a substituent, a C 1-10 alkylthio group which may have a substituent, a substituent A C 2-10 alkenyl group which may have a group or a C 2-10 alkynyl group which may have a substituent;
- a symbol (*) was given to the bond portion with the carbon atom (C) adjacent to R 4 .
- X 4 is a C 1-10 alkyl group which may have a substituent, a C 1-10 alkoxy group which may have a substituent, a C 1-10 alkylthio group which may have a substituent, a substituent A C 2-10 alkenyl group which may have a group, a C 2-10 alkynyl group which may have a substituent, or a C 6-12 aryl group which may have a substituent.
- X 5 is a C 1-10 alkyl group which may have a substituent, a C 1-10 alkoxy group which may have a substituent, a C 1-10 alkylthio group which may have a substituent, a substituent
- a C 2-10 alkenyl group which may have a group, a C 2-10 alkynyl group which may have a substituent, a 5-membered ring group which may have a substituent or a substituent C represents a 6-12 aryl group.
- X 6 represents a C 1-10 alkyl group which may have a substituent, a C 1-10 alkoxy group which may have a substituent, a C 1-10 alkylthio group which may have a substituent, a substituent
- a C 2-10 alkenyl group which may have a group, a C 2-10 alkynyl group which may have a substituent, a 5-membered ring group which may have a substituent or a substituent C represents a 6-12 aryl group.
- X 7 represents a C 1-10 alkyl group which may have a substituent, a C 1-10 alkoxy group which may have a substituent, a C 1-10 alkylthio group which may have a substituent, a substituent
- a C 2-10 alkenyl group which may have a group, a C 2-10 alkynyl group which may have a substituent, a 5-membered ring group which may have a substituent or a substituent C represents a 6-12 aryl group.
- OCT3 organic cation transporter 3
- the activity inhibition ability of OCT3 can be measured by the method shown in the Examples.
- Pharmaceutically acceptable salts refer to derivatives of the disclosed compounds in which the parent compound is modified by making its acidic or basic salts.
- Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines, or alkali or organic salts of acidic residues such as carboxylic acids. Contains salt.
- Pharmaceutically acceptable salts include, for example, the normal non-toxic salts or quaternary ammonium salts of the parent compound formed from non-toxic inorganic or organic acids.
- Such normal non-toxic salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and acetic acid, propionic acid, succinic acid, glycolic acid, stearin.
- inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and acetic acid, propionic acid, succinic acid, glycolic acid, stearin.
- Acid lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamonic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid , Salts prepared from organic acids such as methanesulfonic acid, ethanedisulfonic acid, oxalic acid, and isethionic acid.
- the pharmaceutically acceptable salt forms of the compounds provided herein are synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts for example, form the free acidic or basic form of these compounds with a stoichiometric amount of a suitable base or acid, in water, in an organic solvent, or in a mixture of the two.
- nonaqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
- suitable salts can be found in “Remington's Pharmaceutical Sciences”, 17th. ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is incorporated herein by reference.
- a pharmaceutically acceptable solvate is a solvate of a target compound.
- An example of solvation is hydration.
- Some of the compounds of the present invention have a hydroxyl group or an amide group, and these can form hydrates with moisture in the atmosphere.
- the “C 1-10 alkyl group optionally having substituent (s)” means a C 1-10 alkyl group having one or more substituents selected from the following substituent group A.
- the C 1-10 alkyl group in the C 1-10 alkyl group which may have a substituent is a linear alkyl group having 1 to 10 carbon atoms, a branched alkyl group having 3 to 10 carbon atoms Or a cyclic alkyl group having 3 to 10 carbon atoms. Examples of straight chain alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl.
- branched alkyl groups are isopropyl, isobutyl, 1-methylpropyl, t-butyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1-ethylpropyl, 1,1-dimethyl.
- Propyl group 2,2-dimethylpropyl group, 1,2-dimethylpropyl group, 1-methylpentyl group, 2-methylpentyl group, 3-methylpentyl group, 4-methylpentyl group, 1-ethylbutyl group, 2- Ethylbutyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 1,3-dimethylbutyl group, 2,2-dimethylbutyl group, 2,3-dimethylbutyl group, 3,3-dimethylbutyl group , 5-methylhexyl group, 3-ethylpentyl group, 1-propylbutyl group, 1,4-dimethylpentyl group, 3,4-dimethylpentyl group, 1,2, -Trimethylbutyl group, 1-isopropylbutyl group, 4,4-dimethylpentyl group, 5-methylpentyl group, 6-methylheptyl group, 4-ethylhexyl group,
- cyclic alkyl group examples include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, and a cyclooctyl group.
- a C 1-6 alkyl group is preferable, and a C 1-3 alkyl group is more preferable.
- C 1-6 alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, Neopentyl group, tert-pentyl group, 1-methylbutyl group, 2-methylbutyl group, 1,2-dimethylpropyl group, 1-ethylpropyl group, n-hexyl group, isohexyl group, 1-methylpentyl group, 2-methylpentyl Group, 3-methylpentyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 2,2-dimethylbutyl group, 1-ethylbutyl group, 1,1,2-trimethylpropyl group, 1,2 , 2-trimethylpropyl group, 1-ethyl-2-methylpropyl group, 1-ethyl-1-methylpropyl group.
- the “optionally substituted C 1-10 alkoxy group” means a C 1-10 alkoxy group having one or more substituents selected from the following substituent group A.
- An example of the C 1-10 alkoxy group in the C 1-10 alkoxy group which may have a substituent is a group in which a group represented by —O— is connected to the terminal of the above C 1-10 alkyl group. Specific examples are a methoxy group, an ethoxy group, and a propyloxy group.
- C 1-10 alkylthio group optionally having substituent (s) means a C 1-10 alkylthio group having one or more substituents selected from the following substituent group A.
- An example of the C 1-10 alkylthio group in the C 1-10 alkylthio group which may have a substituent is a group in which a group represented by —S— is connected to the terminal of the above C 1-10 alkyl group.
- the C 2-10 alkenyl group in the optionally substituted C 2-10 alkenyl group has 2 to 10 carbon atoms and is a straight chain alkenyl group having at least one double bond, 3 to 10 A branched alkenyl group having 5 carbon atoms or a cyclic alkenyl group having 5 to 10 carbon atoms.
- Examples thereof include vinyl group, allyl group, 3-butenyl group, 4-pentenyl group, 5-hexenyl group, 6-heptenyl group, 7-octenyl group, 8-nonenyl group, 9-decenyl group, 1 -Methyl-2-butenyl group, 2-methyl-2-butenyl group, 2-methyl-3-butenyl group, 2-pentenyl group, 2-methyl-2-hexenyl group, and 2-cyclopentenyl group.
- a C 2-6 alkenyl group is preferable, and a C 2-3 alkenyl group is more preferable.
- the “optionally substituted C 2-10 alkynyl group” means a C 2-10 alkynyl group having one or more substituents selected from the following substituent group A.
- An alkynyl group is a monovalent group having at least one triple bond (two adjacent SP carbon atoms).
- Examples of C 2-10 alkynyl groups are ethynyl, 1-propynyl, propargyl and 3-butynyl.
- the C 2-10 alkynyl group is preferably a C 2-6 alkynyl group, more preferably a C 2-5 alkynyl group, more preferably a C 2-4 alkynyl group, still more preferably a C 2-3 alkynyl group. Is mentioned.
- the “C 6-12 aryl group optionally having substituent (s)” means a C 6-12 aryl group having one or more substituents selected from the following substituent group A.
- the C 6-12 aryl group may be a heteroaryl group.
- the C 6-12 aryl group in the C 6-12 aryl group which may have a substituent means an aromatic carbocyclic group and an aromatic heterocyclic group.
- Examples of C 6-12 aryl groups include aromatic carbocyclic groups or aromatic heterocyclic groups such as phenyl group, 2-fluorophenyl group, 3-fluorophenyl group, 4-fluorophenyl group, 4-chlorophenyl group.
- Substituent group A A halogen atom, a cyano group, a hydroxyl group, an amino group, a nitro group, a C 1-6 alkyl group, a C 3-6 cycloalkyl group, an optionally substituted C 1-6 alkyl group, or a hydroxyl group.
- a C 1-6 alkyl group a fluorine atom in an optionally substituted C 1-6 alkyl group, a mono C 1-6 alkylamino group, di C 1-6 alkylamino group, C 1-6 alkyl Oxy C 1-6 alkyl group, C 1-6 alkyloxycarbonyl group, (C 1-6 alkyloxycarbonyl) amino group, (C 1-6 alkyloxycarbonyl) C 1-6 alkylamino group, C 1-6 alkylcarbonyl, C 1-6 alkylcarbonyloxy, C 1-6 alkylcarbonylamino group, (C 1-6 alkylcarbonyl) C 1-6 alkylamino , Mono C 1-6 alkylcarbamoyl group, di-C 1-6 alkylcarbamoyl group, mono-C 1-6 alkylcarbamoyl group, di C 1-6 alkylcarbamoyl group, (mono- C 1-6 alkylcarbamoyl) C
- halogen atom examples include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- the “C 3-6 cycloalkyl group” is a cycloalkyl group having 3 to 6 carbon atoms, specifically, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group.
- C 1-6 alkyl group optionally substituted with a fluorine atom includes a C 1-6 alkyl group or a C 1-6 alkyl group in which some or all of the hydrogen atoms are substituted with fluorine atoms.
- 1-6 alkyl groups are included, the latter specifically, fluoromethyl group as C 1-6 alkyl group substituted with a fluorine atom, a difluoromethyl group, a trifluoromethyl group, a 1,2-difluoroethyl group, Is mentioned.
- hydroxy group optionally substituted by a C 1-6 alkyl group C 1-6 alkyl which some of the hydrogen atoms of the C 1-6 alkyl group or a C 1-6 alkyl group is substituted with a hydroxyl group
- Specific examples of the C 1-6 alkyl group that includes a group and is substituted with a hydroxyl group include a hydroxymethyl group, a 2-hydroxyethyl group, and a 3-hydroxypropyl group.
- the "fluorine atoms optionally substituted C 1-6 alkyl group” is a group C 1-6 alkyl group to an oxygen atom is substituted with a C 1-6 alkyl group or a fluorine atom is bonded is included Specifically, C 1-6 alkyloxy groups include methoxy group, ethoxy group, n-propyloxy group, isopropyloxy group, n-butyloxy group, isobutoxy group, tert-butoxy group, n-pentyloxy group and the like.
- Examples of the C 1-6 alkyloxy group substituted with a fluorine atom include a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, and a 1,2-difluoroethoxy group.
- “Mono C 1-6 alkylamino group” is a group in which one of the hydrogen atoms of the amino group is substituted with a C 1-6 alkyl group, specifically, a methylamino group, an ethylamino group, or an n-propylamino group. , Isopropylamino group, n-butylamino group, sec-butylamino group, tert-butylamino group and the like.
- a “di-C 1-6 alkylamino group” is a group in which two hydrogen atoms of an amino group are substituted with a C 1-6 alkyl group. Specifically, a dimethylamino group, a diethylamino group, an ethylmethylamino group, (N-propyl) amino group, methylpropylamino group, diisopropylamino group and the like can be mentioned.
- C 1-6 alkyloxy C 1-6 alkyl group C 1-6 one of the hydrogen atoms of the alkyl group is a group substituted with C 1-6 alkyl group, specifically methoxymethyl group, Examples include ethoxymethyl group, n-propyloxymethyl group, ethoxymethyl group, ethoxyethyl group and the like.
- the “C 1-6 alkyloxycarbonyl group” is a group in which a C 1-6 alkyloxy group is bonded to a carbonyl group, and specifically includes a methoxycarbonyl group, an ethoxycarbonyl group, an n-propyloxycarbonyl group, an isopropyloxy group. Examples include a carbonyl group, n-butyloxycarbonyl group, isobutoxycarbonyl group, tert-butoxycarbonyl group, n-pentyloxycarbonyl group and the like.
- the “(C 1-6 alkyloxycarbonyl) amino group” is a group in which a C 1-6 alkyloxycarbonyl group is bonded to an amino group, specifically, a methoxycarbonylamino group, an ethoxycarbonylamino group, n-propyl. Examples thereof include an oxycarbonylamino group, an isopropyloxycarbonylamino group, an n-butoxycarbonylamino group, an isobutoxycarbonylamino group, a tert-butoxycarbonylamino group, and an n-pentyloxycarbonylamino group.
- (C 1-6 alkyloxycarbonyl) C 1-6 alkylamino group means a group in which a C 1-6 alkyloxycarbonyl group is bonded instead of a hydrogen atom on the nitrogen atom of a mono C 1-6 alkylamino group. Specific examples include (methoxycarbonyl) methylamino group, (ethoxycarbonyl) methylamino group, (n-propyloxycarbonyl) methylamino group, and the like.
- C 1-6 alkylcarbonyl group is a group in which a C 1-6 alkyl group is bonded to a carbonyl group, and specifically includes an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an isovaleryl group, and a pivaloyl group. Groups and the like.
- C 1-6 alkylcarbonyloxy group is a group in which a C 1-6 alkylcarbonyl group is bonded to an oxygen atom, and specifically includes an acetoxy group, a propionyloxy group, a valeryloxy group, an isovaleryloxy group, a pivaloyloxy group. Groups and the like.
- C 1-6 alkylcarbonylamino group is a group in which one of the hydrogen atoms of the amino group is substituted with a C 1-6 alkylcarbonyl group, specifically, an acetamido group, a propionylamino group, an isobutyrylamino group , Valerylamino group, isovalerylamino group, pivaloylamino group and the like.
- (C 1-6 alkylcarbonyl) C 1-6 alkylamino group is a group in which a hydrogen atom on a nitrogen atom of a mono C 1-6 alkylamino group is substituted with a C 1-6 alkylcarbonyl group, And methylcarbonyl) methylamino group, (ethylcarbonyl) methylamino group, (n-propylcarbonyl) methylamino group, and the like.
- “Mono C 1-6 alkylcarbamoyl group” is a group in which one hydrogen atom of a carbamoyl group is substituted with a C 1-6 alkyl group, and specifically includes a methylcarbamoyl group, an ethylcarbamoyl group, an n-propylcarbamoyl group. , Isopropylcarbamoyl group, n-butylcarbamoyl group, sec-butylcarbamoyl group, tert-butylcarbamoyl group, and the like.
- the “di-C 1-6 alkylcarbamoyl group” is a group in which two hydrogen atoms of a carbamoyl group are substituted with a C 1-6 alkyl group, specifically, a dimethylcarbamoyl group, a diethylcarbamoyl group, an ethylmethylcarbamoyl group, Examples include di (n-propyl) carbamoyl group, methylpropylcarbamoyl group, diisopropylcarbamoyl group and the like.
- the “mono C 1-6 alkylcarbamoylamino group” is a group in which one hydrogen atom of an amino group is substituted with a C 1-6 alkylcarbamoyl group, and specifically includes a methylcarbamoylamino group, an ethylcarbamoylamino group, n -Propylcarbamoylamino group, isopropylcarbamoylamino group, n-butylcarbamoylamino group, sec-butylcarbamoylamino group, tert-butylcarbamoylamino group and the like.
- the “di-C 1-6 alkylcarbamoylamino group” is a group in which one hydrogen atom of the amino group is substituted with a di-C 1-6 alkylcarbamoyl group, specifically, a dimethylcarbamoylamino group, a diethylcarbamoylamino group, Examples thereof include a di (n-propyl) carbamoylamino group, a diisopropylcarbamoylamino group, a di (n-butyl) carbamoylamino group, a di (sec-butyl) carbamoylamino group, and a di (tert-butyl) carbamoylamino group.
- a “(mono C 1-6 alkylcarbamoyl) C 1-6 alkylamino group” is a group in which the hydrogen atom on the nitrogen atom of the “mono C 1-6 alkylamino group” is substituted with the mono C 1-6 alkylcarbamoyl group.
- Specific examples include (monomethylcarbamoyl) methylamino group, (monoethylcarbamoyl) methylamino group, [mono (n-propyl) carbamoyl] methylamino group, and the like.
- (DiC 1-6 alkylcarbamoyl) C 1-6 alkylamino group is a group in which the hydrogen atom on the nitrogen atom of the mono-C 1-6 alkylamino group is substituted with a diC 1-6 alkylcarbamoyl group. Specific examples include (dimethylcarbamoyl) methylamino group, (diethylcarbamoyl) methylamino group, [di (n-propyl) carbamoyl] methylamino group, and the like.
- the “mono C 1-6 alkylcarbamoyloxy group” is a group in which a C 1-6 alkylcarbamoyl group is bonded to an oxygen atom, specifically, a methylcarbamoyloxy group, an ethylcarbamoyloxy group, or an n-propylcarbamoyloxy group. , Isopropylcarbamoyloxy group, n-butylcarbamoyloxy group, sec-butylcarbamoyloxy group, tert-butylcarbamoyloxy group, and the like.
- the “di-C 1-6 alkylcarbamoyloxy group” is a group in which a di-C 1-6 alkylcarbamoyl group is bonded to an oxygen atom, specifically, a dimethylcarbamoyloxy group, a diethylcarbamoyloxy group, an ethylmethylcarbamoyloxy group. , Di (n-propyl) carbamoyloxy group, methylpropylcarbamoyloxy group, diisopropylcarbamoyloxy group and the like.
- C 1-6 alkylsulfonyl group is a group in which a C 1-6 alkyl group is bonded to a sulfonyl group, specifically a methylsulfonyl group, an ethylsulfonyl group, an n-propylsulfonyl group, an isopropylsulfonyl group, an n -Butylsulfonyl group, sec-butylsulfonyl group, tert-butylsulfonyl group and the like.
- C 1-6 alkylsulfonylamino group is a group in which one hydrogen atom of an amino group is substituted with a C 1-6 alkylsulfonyl group, and specifically includes a methylsulfonylamino group, an ethylsulfonylamino group, n- Examples include propylsulfonylamino group, isopropylsulfonylamino group, n-butylsulfonylamino group, sec-butylsulfonylamino group, tert-butylsulfonylamino group and the like.
- C 1-6 alkylsulfonyl (C 1-6 alkyl) amino group is a group in which a hydrogen atom on a nitrogen atom of “C 1-6 alkylamino group” is substituted with a C 1-6 alkylsulfonyl group, Specific examples include a methylsulfonyl (methyl) amino group, an ethylsulfonyl (methyl) amino group, and an (n-propyl) sulfonyl (methyl) amino group.
- the “mono C 1-6 alkylsulfamoyl group” is a group in which a C 1-6 alkyl group is bonded to a sulfamoyl group. Specifically, a monomethylsulfamoyl group, a monoethylsulfamoyl group, a mono (n -Propyl) sulfamoyl group, monoisopropylsulfamoyl group, mono (n-butyl) sulfamoyl group, mono (sec-butyl) sulfamoyl group, mono (tert-butyl) sulfamoyl group and the like.
- the “di-C 1-6 alkylsulfamoyl group” is a group in which a di-C 1-6 alkyl group is bonded to a sulfamoyl group. Specifically, a dimethylsulfamoyl group, a diethylsulfamoyl group, a di (n -Propyl) sulfamoyl group, diisopropylsulfamoyl group, di (n-butyl) sulfamoyl group, di (sec-butyl) sulfamoyl group, di (tert-butyl) sulfamoyl group and the like.
- the “(mono C 1-6 alkylsulfamoyl) amino group” is a group in which one hydrogen atom of the amino group is substituted with a mono C 1-6 alkylsulfamoyl group. Moyl) amino group, (monoethylsulfamoyl) amino group, [mono (n-propyl) sulfamoyl] amino group, (monoisopropylsulfamoyl) amino group, [mono (n-butyl) sulfamoyl] amino group, [ And mono (sec-butyl) sulfamoyl] amino group, (tert-butylsulfamoyl) amino group, and the like.
- the “(diC 1-6 alkylsulfamoyl) amino group” is a group in which one hydrogen atom of the amino group is substituted with a diC 1-6 alkylsulfamoyl group. Moyl) amino group, (diethylsulfamoyl) amino group, (ethylmethylsulfamoyl) amino group, [di (n-propyl) sulfamoyl] amino group, (methylpropylsulfamoyl) amino group, (diisopropylsulfa Moyl) amino group and the like.
- “Mono C 1-6 alkylsulfamoyl (C 1-6 alkyl) amino group” means that the hydrogen atom on the nitrogen atom of “mono C 1-6 alkylamino group” is a mono C 1-6 alkylsulfamoyl group Specific examples include monomethylsulfamoyl (methyl) amino group, monoethylsulfamoyl (methyl) amino group, mono (n-propyl) sulfamoyl (methyl) amino group, and the like.
- “Di-C 1-6 alkylsulfamoyl (C 1-6 alkyl) amino group” means that the hydrogen atom on the nitrogen atom of “mono-C 1-6 alkylamino group” is a di-C 1-6 alkylsulfamoyl group Specific examples include a dimethylsulfamoyl (methyl) amino group, a diethylsulfamoyl (methyl) amino group, and a di (n-propyl) sulfamoyl (methyl) amino group.
- Examples of the “3- to 8-membered heterocycloalkyl group” include azetidinyl group, pyrrolidinyl group, piperidinyl group, piperazinyl group, imidazolidinyl group, tetrahydrofuranyl group, tetrahydropyranyl group, morpholinyl group, 1-thia-4-azocyclohexyl group 2,5-diazabicyclo [2.2.2] octaneyl group and the like.
- Examples of preferred first groups of compounds of the invention are as follows: That is, in the compound represented by the formula (I), R 1 , R 2 , R 3 , R 5 and R 6 represent a hydrogen atom or a methyl group, and R 4 represents a group represented by the formula (II). Indicates. In this embodiment, it is preferable that R 1 , R 3 , R 5 and R 6 represent a hydrogen atom and R 2 represents a methyl group.
- X 2 represents a group represented by —Y 21 —Y 22 —Y 23 , or —Y 21 —Y 22 (—Y 23 Y 24 ).
- Y 21 represents a linear or branched C 1-5 alkylene group.
- Y 22 represents a single bond, an oxygen atom, a sulfur atom, or a group represented by SO 2 (—S ( ⁇ O) 2 —).
- X 2 may represent a group represented by —Y 25 (Y 26 ) —Y 27 .
- a phenyl group in which 1 to 3 hydrogen atoms may be substituted with the group represented by Y 26 represents a hydrogen atom, a phenyl group, C 3-5 cycloalkyl group, C 1-5 alkyl may pyrrolidinyl group optionally substituted by a group, or a C 1-5 alkyl may pyrrole group optionally substituted with a group .
- Preferred compounds of the first group are those represented by formula (I), wherein R 1 , R 2 , R 3 , R 5 and R 6 represent a hydrogen atom or a methyl group, and R 4 represents formula (II). Represents a group.
- X 2 represents any group represented by the following formulas (1-1) to (1-26). In this embodiment, it is more preferable that R 1 , R 3 , R 5 and R 6 represent a hydrogen atom and R 2 represents a methyl group.
- R 1 , R 2 , R 3 , R 5 and R 6 represent a hydrogen atom or a methyl group
- R 4 represents a group represented by the formula (III).
- X 3 represents a group represented by the following formula (2-1) or (2-2).
- R 1 , R 3 , R 5 and R 6 represent a hydrogen atom and R 2 represents a methyl group.
- a third group of the compounds of the present invention is represented by formula (I), wherein R 1 , R 2 , R 3 , R 5 and R 6 represent a hydrogen atom or a methyl group, and R 4 represents formula (IV) Indicates the group shown.
- X 4 represents any group represented by the following formulas (3-1) to (3-4). In this embodiment, it is preferred that R 1 , R 3 , R 5 and R 6 represent a hydrogen atom and R 2 represents a methyl group.
- a fourth group of compounds of the present invention is represented by the formula (I) wherein R 1 , R 2 , R 3 , R 5 and R 6 represent a hydrogen atom or a methyl group, and R 4 represents the formula (V). Represents a group.
- X 5 represents any group represented by the following formulas (4-1), (5-1), (5-2), or (6-1).
- R 1 represents a methyl group
- R 2 , R 3 , R 5 and R 6 represent a hydrogen atom
- X 5 is represented by formula (4-1)
- the group shown, R 1 , R 2 , R 5 and R 6 each represent a hydrogen atom and R 3 represents a methyl group
- X 5 represents formula (5-1) or (5-2)
- a group represented by R 1 , R 2 , R 3 , R 5 and R 6 are each preferably a hydrogen atom
- X 5 is preferably any group represented by (6-1).
- a fifth group of compounds of the present invention is represented by the formula (I) wherein R 1 , R 2 , R 3 , R 5 and R 6 represent a hydrogen atom or a methyl group, and R 4 represents the formula (VI). Represents a group.
- X 6 represents any group represented by the following formula (7-1) or (7-4). In this embodiment, it is preferable that R 1 , R 2 , R 3 , R 5 and R 6 represent a hydrogen atom. Note in the formula (7-4), the coupling portion between the carbon atom adjacent to X 6 (C), to confer symbol (*), and explicit binding site.
- a sixth group of the compounds of the present invention is represented by formula (I), wherein R 1 , R 2 , R 3 , R 5 and R 6 represent a hydrogen atom or a methyl group, and R 4 represents formula (VII) Indicates the group shown.
- X 7 represents any group represented by the following formulas (8-1) and (8-2). In this embodiment, it is preferable that R 1 , R 2 , R 3 , R 5 and R 6 represent a hydrogen atom.
- An activity inhibitor of OCT3 containing the compound of the present invention can be produced in the same manner as the method disclosed in Re-Table 2005/084707.
- Examples of the activity of OCT3 are transport activities of dopamine, serotonin, noradrenaline, dopamine neurotoxin MPP +, stimulant and the like. These activities can be measured by techniques known to those skilled in the art.
- An activity inhibitor of OCT3 containing the compound of the present invention is effective for the treatment of diseases (depression and depression-like symptoms) involving OCT3.
- diseases depression and depression-like symptoms
- inhibition of the organic cation transporter OCT3 can treat depression and depression-like symptoms.
- the expression of the mouse OCT3 gene is suppressed by antisense or knockout technology. It has been reported that it exhibits antidepressant action in the forced swimming test.
- the present OCT3 inhibitor inhibits the function of the OCT3 protein, it is presumed to have the same action as suppressing the expression of the OCT3 gene.
- the compound of the present invention has OCT3 inhibitory activity. Therefore, the present invention also provides a therapeutic agent for depression and depression-like symptoms comprising the above-mentioned inhibitor of OCT3 as an active ingredient.
- Depression and depression-like symptoms include physical depression, unipolar depression, psychogenic functional illness, atypical depression, dysthymia, bipolar affective illness, seasonal depression, persistent mood disorders.
- the compound of the present invention can be administered orally or parenterally, and can be formulated into a form suitable for its administration.
- a pharmaceutically acceptable carrier according to the administration form and administer it after various preparations.
- various conventionally known additives in the pharmaceutical field can be used, for example, gelatin, lactose, sucrose, titanium oxide, starch, crystalline cellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, corn starch, microcrystalline.
- Wax white petrolatum, magnesium aluminate metasilicate, anhydrous calcium phosphate, citric acid, trisodium citrate, hydroxypropylcellulose, sorbitol, sorbitan fatty acid ester, polysorbate, sucrose fatty acid ester, polyoxyethylene, hydrogenated castor oil, polyvinyl Pyrrolidone, magnesium stearate, light anhydrous silicic acid, talc, vegetable oil, benzyl alcohol, gum arabic, propylene glycol, polyalkylene glycol, Cyclodextrin or hydroxypropyl cyclodextrin and the like.
- dosage forms formulated as a mixture of these carriers and the compound of the present invention include solid preparations such as tablets, capsules, granules, powders or suppositories; or syrups, elixirs or injections, etc. These can be prepared according to a conventionally known method in the pharmaceutical field. In the case of a liquid preparation, it may be dissolved or suspended in water or other appropriate medium at the time of use. In particular, in the case of injections, they may be dissolved or suspended in physiological saline or glucose solution as necessary, and buffering agents and preservatives may be added.
- These preparations can contain the compound of the present invention in a proportion of 1.0 to 100% by weight, preferably 1.0 to 60% by weight of the total pharmaceutical composition, and contain a pharmaceutically acceptable carrier. It can be contained in an amount of 0 to 99.0% by weight, preferably 40 to 99.0% by weight.
- the dose and the number of administrations are the patient's sex, age, weight, degree of symptom, type and range of desired therapeutic effect, etc.
- 0.001 to 10 mg, preferably 0.01 to 2 mg per kg body weight per day for an adult is preferably administered in 1 to several divided doses. Depending on the symptoms, it can be administered prophylactically.
- the detecting agent for OCT3 containing the compound of the present invention detects whether the OCT3 protein is contained in biological tissues, cultured cells, artificial membranes, etc. for which the abundance of the OCT3 protein is to be confirmed. Or, it is an agent for obtaining an index of the content of the OCT3 protein.
- An aqueous detection agent solution containing the compound of the present invention is added dropwise to a biological tissue, cultured cell, artificial membrane or the like for which the amount of OCT3 protein is to be confirmed. Then, since the compound of the present invention binds to the OCT3 protein, the concentration of the compound of the present invention in the aqueous solution decreases.
- OCT3 protein when the concentration of the compound of the present invention in an aqueous solution is measured and the concentration of the compound of the present invention decreases, it can be seen that OCT3 protein is present.
- Antibodies against the OCT3 protein are commercially available and can be used as detection agents. However, since antibodies are high molecular weight proteins, they are vulnerable to heat and must be stored at low temperatures. In addition, since an antibody is a high molecular protein, it is difficult to store for a long time, and the production cost is high. On the other hand, the compounds of the present invention are resistant to heat, can be stored for a long time at room temperature, and can be produced at a relatively low cost by chemical synthesis.
- HEK293 cells which are human embryonic kidney cell lines expressing human organic cation transporter 3 (hOCT3), were used.
- HEK293 cells were seeded in a 24-well plate at 1.5 ⁇ 10 5 cells / well and cultured overnight in a carbon dioxide incubator.
- HBSS-HEPES solution (9.7 g Hanks balanced salt, 25 mL of 1.4% sodium bicarbonate, 25 mL of 1M HEPES is dissolved in 940 mL of ultrapure and adjusted to pH 7.4 with 1 M sodium hydroxide.
- the cells were pretreated with 1 mL of HBSS-HEPES solution for 5 minutes. Then test substance and [3 H] histamine (final concentration 100 nM) was added to the cells and allowed to react for 1 minute at room temperature. After completion of the reaction, the reaction was stopped with an ice-cooled HBSS-HEPES solution, the extracellular fluid was removed by suction with an aspirator, and then washed twice with the HBSS-HEPES solution. After washing, the cells were lysed with a 0.5 M aqueous sodium hydroxide solution. The amount of histamine present in the cells was determined by measuring the radioactivity in the cell lysate with a liquid scintillation counter.
- cell lysate was used to determine the amount of protein in the cells using the Lowry method ( Biol Chem. 1951; 193 (1): 265-75).
- the histamine uptake rate (%) in the presence of 30 ⁇ M of the test substance was calculated assuming that the histamine uptake amount per protein amount in the absence of an uptake inhibitor was the histamine uptake rate 100% (control). Further, a value (%) obtained by subtracting the histamine uptake rate from 100 (%) was calculated as an OCT3 inhibition rate (%).
- the OCT3 inhibitory activity (IC 50 value) was calculated from the inhibition curve at 10 ⁇ 7 to 10 ⁇ 3 M concentration of the test substance.
- the Brain / Blood values predicted by the above method were verified by experiments using BALB / c mice.
- test substances in the verification experiment two compounds were used: Compound SR-4277, which has been confirmed to have a strong OCT3 inhibitory action, and Famotidine, which has been confirmed to have both an OCT3 inhibitory action and an antidepressant action.
- the test substance was administered to the mouse at 5 mg / kg, anesthetized with isoflurane in advance, and after 5 minutes from the administration, whole blood was collected from the hind vena cava of the mouse, the brain was removed and weighed, and a brain homogenate was prepared. The collected blood was centrifuged to prepare plasma, and the concentration of the test substance in plasma and brain homogenate was measured using HPLC and MS. Brain / Blood prediction and actual measurement results are shown below.
- the result of the verification experiment shows that the predicted value and the actual measured value are very close (close order), and the prediction method of the above-mentioned Brain / Blood value has very good prediction accuracy. It can be said that. This method was also applied to other compounds, and Brain / Blood values were calculated.
- each compound not only has excellent OCT3 inhibitory activity, but also has excellent practicality as an oral agent or a central drug, and has been confirmed to have an OCT3 inhibitory action (Non-patent Document 2) and an antidepressant action (Patent Document 4).
- OCT3 inhibitory activity has been obtained compared to famotidine, which can be expected to be useful in the treatment of depression and the like.
- the IC 50 values and at the same time strong famotidine IC 50 values of the measured OCT3 inhibitory activity as compared to some of the compounds were as follows.
- SR-4277 has an IC 50 of 8.2 ⁇ M and IC 80 of 30 ⁇ M, and has strong inhibitory activity. Since OCT3 is very similar in amino acid sequence to OCT1 and OCT2, it is easily imagined that a compound having OCT3 inhibitory activity has OCT1 and OCT2 inhibitory activity.
- the imidazopyridine derivative of the present invention is a strong inhibitor of OCT3 protein and is useful as a detection agent for OCT3.
- the imidazopyridine derivative When an imidazopyridine derivative aqueous solution is dropped in a biological tissue, a cultured cell, an artificial membrane or the like for which the abundance of the OCT3 protein is to be confirmed, the imidazopyridine derivative is bound to the OCT3 protein, so that the concentration of the imidazopyridine derivative in the aqueous solution decreases. When this concentration decreases, it can be seen that OCT3 protein is present.
- the method for detecting OCT3 protein can be realized by a histamine uptake experiment described below.
- OCT3 protein For example, histamine uptake experiments were performed according to the method described in Br J Pharmacol. 2002; 136 (6): 829-836, and released into the extracellular fluid in the same manner as the method described in Japanese Patent No. 1936624.
- the amount of OCT3 protein present can be estimated from the amount of the compound.
- HEK293 cell which is a human fetal kidney cell line expressing human type organic cation transporter 3 (OCT3)
- OCT3 expression is to be confirmed is prepared as a test cell.
- Each cell is seeded in a 24-well plate at 1.5 ⁇ 10 5 cells / well and cultured overnight in a carbon dioxide incubator.
- test substance was dissolved in 100% DMSO solution, and then HBSS-HEPES solution (9.7 g Hanks balanced salt, 1.4% sodium bicarbonate 25 mL, 1 M HEPES 25 mL was dissolved in ultrapure 940 mL and pH 7 with 1 M sodium hydroxide was added. (4. buffer adjusted to 4). After removing the cell culture medium, pretreat with 1 mL of HBSS-HEPES solution for 5 minutes. Thereafter, the compound of the present invention as a test substance and histamine (final concentration 100 nM) are added to the cells and allowed to react at room temperature for 1 minute. After completion of the reaction, the reaction is stopped with an ice-cooled HBSS-HEPES solution, and the extracellular fluid is recovered.
- HBSS-HEPES solution 9.7 g Hanks balanced salt, 1.4% sodium bicarbonate 25 mL, 1 M HEPES 25 mL was dissolved in ultrapure 940 mL and pH 7 with 1 M sodium hydroxide was added
- the concentration and abundance of the compound of the present invention in the extracellular fluid can be identified.
- the amount of compound in the extracellular fluid recovered from the amount of compound thus administered the amount of compound bound to OCT3 can be calculated, and the presence of OCT3 protein in the cell can be confirmed.
- Another method for estimating the concentration of the compound of the present invention in the extracellular fluid is as follows. A plurality of standard solutions are prepared in advance for the compound of the present invention, and the absorbance is measured in advance. Next, the absorbance of the extracellular fluid collected in the above histamine uptake experiment is measured, and the concentration is easily estimated without using LC / MS by comparing the measured value with the standard solution measured in advance. it can.
- An antibody against OCT3 protein is commercially available and can be used as a detection agent.
- the antibody is a high molecular weight protein, it is weak against heat (stored at 4 ° C), difficult to store for a long time, and the production cost is low. Expensive.
- imidazopyridine derivatives are resistant to heat, can be stored for a long time at room temperature, and can be produced by inexpensive chemical synthesis.
- Example 2 relates to an evaluation method for antidepressant action and antidepressant-like symptoms.
- the most widely used method for evaluating antidepressant action is the forced swimming test developed by Porsolt et al. (Porsolt RD. Et al, Arch Int Pharmacodyn. 1977; 229: 327-336).
- forced swimming is applied to a mouse or rat that cannot escape as a test animal. Then, after the escape behavior of the test animal, immobile behavior (a state in which only the head is raised on the surface of the water and floating without moving the limbs) is observed.
- immobile behavior a state in which only the head is raised on the surface of the water and floating without moving the limbs
- the test animal is placed in the water tank again after 24 hours or more, the immobility behavior appears earlier than the first experiment, and this immobility behavior during a certain time (usually around 5 minutes). The duration of is reproduced relatively accurately.
- test designs using this method.
- a standard antidepressant eg, a tricyclic antidepressant
- a buffer containing no drug is given as a negative control to each animal.
- the experimental condition of the forced swimming test is set so that it can detect the “changes in”.
- the test substance is then administered on the same schedule as the positive control drug, and if it is confirmed that the test substance causes the same behavioral change as the positive control drug, the antidepressant action is the same clinical effect as the positive control drug.
- test drug can be expected (Yu Nakagawa, Practical Behavioral Pharmacology, Kinyoshido, 2010, p35-42).
- Example 3 relates to the confirmation of the antidepressant effect by the OCT3 inhibitor and the combined use effect with the antidepressant imipramine.
- ddY male mice Japan SLC Co., Ltd. weighing 28 to 33 g are used.
- the ddY mouse is an outbred mouse with high reproductive capacity and good growth, and is a laboratory mouse widely used in various research studies including drug efficacy, pharmacology, and toxicity tests. This is a typical system name.
- After obtaining this mouse keep it in a room with controlled temperature (22-24 ° C), humidity (50-60%), and lighting (lights from 8 am to 8 pm) for at least 3 days.
- all experimental mice were allowed to swim for 300 seconds in a glass cylinder (diameter 15.5 cm, depth 17 cm, water depth 12 cm, water temperature 25 ° C.), and the immobility time was measured.
- OCT3 inhibitor administration group positive control group, negative control group
- mice that developed immobility time with a difference of 60 seconds or more from the average immobility time (long or short) are excluded from the experiment.
- the water in the aquarium should be changed for each mouse.
- physiological buffer 140 mM NaCl, 3.0 mM
- An OCT3 inhibitor dissolved in KCl, 1.5 mM NaH2PO4, 1.2 mM MgCl2, 1.2 mM CaCl2, pH 7.4 has been reported (J. Chem. Neuroanat. 2000).
- the immobility time in the forced swimming test was comparable to that of the negative control. It is expected that there is no difference (both average immobility time is about 200 seconds), but when both are used together, it can be expected that the immobility will be significantly shortened compared to the negative control (The average value of stationary time is about 100 seconds). If the above results are obtained, the antidepressant action of the OCT3 inhibitor can be confirmed, and the combined use with imipramine can also be confirmed.
- mice DdY male mice are used for the experiment. Mice that had been bred for 3 days or more after purchase were divided into 2 groups. One group received an OCT3 inhibitor previously reported (J. Chem. Neuroanat. 2000). 20: 375-87), continuously infused into the third ventricle with an osmotic pump. Another group performs sham surgery and injects physiological buffer into the third ventricle instead of an OCT3 inhibitor as a negative control. One week after the injection, the mouse is placed in a plastic cage (30 cm x 35 cm x 17 cm), and the amount of locomotor activity before and after intravenous administration of the stimulant methamphetamine (1 mg / kg) is measured.
- Spontaneous momentum is automatically counted by an infrared sensor (Merquest, SCANET SV-10) attached to the wall. From 120 minutes before the administration of the stimulant methamphetamine to immediately before administration, the locomotor activity in the negative control group and in the OCT3 inhibitor group were measured, and from immediately after methamphetamine administration to 180 minutes after administration, the stimulant in each group Measure the induced locomotor activity. After the measurement, a significant difference test using the Scheffe method is performed on the counts of the spontaneous momentum of each group to determine whether the spontaneous momentum changes statistically (p value is less than 0.05).
- the present invention can be used in the pharmaceutical industry.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
R1~R3及びR5~R6は,同一でも異なってもよく,
水素原子,ハロゲン原子,C1-3アルキル基,C1-3アルコキシ基,C1-3アルキルチオ基,又はC1-3ハロゲノアルキル基を示し,
R4は,式(II)~式(VII)のいずれかの基を示す。
X2は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基又は置換基を有しても良いC2-10アルキニル基を示す。
X3は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基又は置換基を有しても良いC2-10アルキニル基を示す。なお式(III)において,R4に隣接する炭素原子(C)との結合部分に記号(*)を付与した。
X4は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基,置換基を有しても良いC2-10アルキニル基,又は置換基を有しても良いC6-12アリール基を示す。
X5は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基,置換基を有しても良いC2-10アルキニル基,置換基を有してよい5員環の基又は置換基を有しても良いC6-12アリール基を示す。
X6は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基,置換基を有しても良いC2-10アルキニル基,置換基を有してよい5員環の基又は置換基を有しても良いC6-12アリール基を示す。
X7は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基,置換基を有しても良いC2-10アルキニル基,置換基を有してよい5員環の基又は置換基を有しても良いC6-12アリール基を示す。
R1~R3及びR5~R6は,同一でも異なってもよく,水素原子,ハロゲン原子,C1-3アルキル基,C1-3アルコキシ基,C1-3アルキルチオ基,又はC1-3ハロゲノアルキル基を示す。R1~R3及びR5~R6の好ましい例は,水素原子,又はC1-3アルキル基である。ここで,C1-3アルキル基として,メチル基又はエチル基が好ましい。
X2は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基又は置換基を有しても良いC2-10アルキニル基,置換基を有しても良いC6-10アリール基,又は置換基を有してもよい良いC7-10アラルキル基を示す。
X3は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基又は置換基を有しても良いC2-10アルキニル基を示す。なお式(III)において,R4に隣接する炭素原子(C)との結合部分に記号(*)を付与した。
X4は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基,置換基を有しても良いC2-10アルキニル基,又は置換基を有しても良いC6-12アリール基を示す。
X5は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基,置換基を有しても良いC2-10アルキニル基,置換基を有してよい5員環の基又は置換基を有しても良いC6-12アリール基を示す。
X6は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基,置換基を有しても良いC2-10アルキニル基,置換基を有してよい5員環の基又は置換基を有しても良いC6-12アリール基を示す。
X7は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基,置換基を有しても良いC2-10アルキニル基,置換基を有してよい5員環の基又は置換基を有しても良いC6-12アリール基を示す。
ed.,Mack Publishing Company,Easton,PA,1985,p.1418に見出され,その開示は参照により本明細書に取り込まれる。
ハロゲン原子,シアノ基,水酸基,アミノ基,ニトロ基,C1-6アルキル基,C3-6シクロアルキル基,フッ素原子で置換されていてもよいC1-6アルキル基,水酸基で置換されていてもよいC1-6アルキル基,フッ素原子で置換されていてもよいC1-6アルキルオキシ基,モノC1-6アルキルアミノ基,ジC1-6アルキルアミノ基,C1-6アルキルオキシC1-6アルキル基,C1-6アルキルオキシカルボニル基,(C1-6アルキルオキシカルボニル)アミノ基,(C1-6アルキルオキシカルボニル)C1-6アルキルアミノ基,C1-6アルキルカルボニル基,C1-6アルキルカルボニルオキシ基,C1-6アルキルカルボニルアミノ基,(C1-6アルキルカルボニル)C1-6アルキルアミノ基,モノC1-6アルキルカルバモイル基,ジC1-6アルキルカルバモイル基,モノC1-6アルキルカルバモイルアミノ基,ジC1-6アルキルカルバモイルアミノ基,(モノC1-6アルキルカルバモイル)C1-6アルキルアミノ基,(ジC1-6アルキルカルバモイル)C1-6アルキルアミノ基,モノC1-6アルキルカルバモイルオキシ基,ジC1-6アルキルカルバモイルオキシ基,C1-6アルキルスルホニル基,C1-6アルキルスルホニルアミノ基,C1-6アルキルスルホニル(C1-6アルキル)アミノ基,モノC1-6アルキルスルファモイル基,ジC1-6アルキルスルファモイル基,(モノC1-6アルキルスルファモイル)アミノ基,(ジC1-6アルキルスルファモイル)アミノ基,モノC1-6アルキルスルファモイル(C1-6アルキル)アミノ基,ジC1-6アルキルスルファモイル(C1-6アルキル)アミノ基,3~8員のヘテロシクロアルキル基,芳香族炭素環基及び芳香族複素環基。
X2は,-Y21-Y22-Y23,又は-Y21-Y22(-Y23Y24)で示される基を示す。そして,Y21は,直鎖又は分岐のC1-5アルキレン基を示す。Y22は,単結合,酸素原子,硫黄原子,又はSO2で示される基(-S(=O)2-)を示す。
水素原子;
C1-5アルキル基,
C3-6シクロアルキル基;
メチル基,=Oで示される基(カルボニル基)又はハロゲン原子で置換されても良い,ピロリジニル(pyrrolidinyl)基;
メチル基,=Oで示される基(カルボニル基)又はハロゲン原子で置換されても良い,チアゾリジニル(thiazolidinyl)基;
直鎖又は分岐のC1-5アルキル基に接続されたフェニル基;
直鎖又は分岐のC1-5アルキル基に接続されたC1-5アルコキシ基で置換されたフェニル基;
ハロゲン原子,ニトロ基,C1-5アルキル基,C1-5アルコキシ基,C1-5ハルゲノアルキル基,C1-5ハルゲノアルコキシ基,ピロリジニル(pyrrolidinyl)基,=Oで示される基(カルボニル基)で置換されたピロリジニル(pyrrolidinyl)基;又は
ベンゾイミダゾリル(benzomidazolyl)基;
を示す。
Y25は,ハロゲン原子,ニトロ基,C1-5アルキル基,C1-5アルコキシ基,C1-5ハルゲノアルキル基,C1-5ハルゲノアルコキシ基,ピロリジニル(pyrrolidinyl)基,=Oで示される基で1~3個の水素原子が置換されても良いフェニル基を示す。
Y26は,水素原子,フェニル基,C3-5シクロアルキル基,C1-5アルキル基で置換されても良いピロリジニル基,又はC1-5アルキル基で置換されても良いピロール基を示す。
Y27は,
水素原子;
ハロゲン原子;
C3-5シクロアルキル基,
直鎖又は分岐のC1-5アルキル基に接続されたピロリジニル(pyrrolidinyl)基;
直鎖又は分岐のC1-5アルキル基に接続されたピペリジニル(piperidinyl)基;
ジオキソラニル(dioxolanyl)基;
イミダゾリル(midazolyl)基;
-C(=O)-CH3で示される基;
-C(=O)-NH2で示される基;
-C(=O)-NC5H10で示される基;
-S(O2)NHCH3で示される基;
-S(O2)NHC3H7で示される基;
-NC(=O)OCH3で示される基;
-NC(=O)C3H5で示される基;
-NC(=O)C3H7で示される基;又は
を示す。
R1,R2,R5及びR6が水素原子を示し,R3がメチル基を示すものであって,式(V)中,X5が式(5-1)又は(5-2)で示される基であるもの,又は,
R1,R2,R3,R5及びR6が水素原子を示し,式(V)中,X5が(6-1)で示されるいずれかの基を示すものが好ましい。なお式(4-1),(5-2),(6-1)において,X5に隣接する硫黄原子(S)との結合部分に,記号(*)を付与することで,結合部位を明示した。
本発明の化合物を含むOCT3の検出剤は,OCT3蛋白質の存在量を確認したい生物組織や培養細胞,人工膜等にOCT3蛋白質が含まれているか否か検出するか,OCT3蛋白質の含有量の指標を得るための剤である。OCT3蛋白質の存在量を確認したい生物組織や培養細胞,人工膜等に本発明の化合物等を有する検出剤水溶液を滴下する。すると,本発明の化合物がOCT3蛋白質に結合するため,水溶液の本発明の化合物濃度が減少する。すなわち,水溶液における本発明の化合物の濃度を測定し,本発明の化合物の濃度が減少した場合,OCT3蛋白質が存在していることがわかる。OCT3蛋白質に対する抗体が市販されており,検出剤として利用することができる。しかしながら,抗体は高分子蛋白質であることから,熱に弱いため低温で保存する必要がある。また,抗体は高分子蛋白質であることから,長期保存が困難であり,製造費用が高価である。一方,本発明の化合物等は,熱に強く,常温で長期保存が可能で,化学合成により比較的安価に製造できる。
J Pharmacol. 2002; 136(6): 829-836 に掲載された方法に従ってヒスタミン取込実験を行った。この実験において,ヒト型有機カチオントランスポーター3(hOCT3)を発現したヒト胎児腎細胞株であるHEK293細胞を用いた。HEK293細胞を24ウェルプレートに1.5×105 細胞/ウェルにて播種し,炭酸ガスインキュベーター内にて一晩培養した。被験物質を100%DMSO溶液に溶解した後,HBSS-HEPES溶液(9.7g ハンクス平衡塩, 1.4%炭酸水素ナトリウム25mL,1M HEPES 25mLを超純粋940mLに溶解して1M水酸化ナトリウムでpH7.4に調整した緩衝液)に溶解した。細胞培養用培地を除去した後,HBSS-HEPES溶液 1mLで5分間前処置した。その後,被験物質および[ 3 H]ヒスタミン(最終濃度 100
nM)を細胞に添加し,室温にて1分間反応させた。反応終了後,氷冷したHBSS-HEPES溶液で反応を停止し,アスピレーターにて細胞外液を吸引除去後,HBSS-HEPES溶液で2回洗浄した。洗浄後,0.5Mの水酸化ナトリウム水溶液にて細胞を溶解した。細胞内に存在するヒスタミン量は,細胞溶解液中の放射活性を液体シンチレーションカウンターで測定することにより求めた。また細胞溶解液を用いて細胞のタンパク量をLowry法(J
Biol Chem. 1951;193(1):265-75)により測定した。取込阻害剤がない場合におけるタンパク量当たりのヒスタミン取込量をヒスタミン取込率100%(control)とし,30μMの被験物質存在下のヒスタミン取込率(%)を算出した。またこのヒスタミン取込率を100(%)から減算した値(%)をOCT3阻害率(%)として算出した。また,被験物質の10-7 ~10-3 M濃度での抑制曲線からOCT3阻害活性(IC50値)を算出した。
各化合物のlogP をMarvinソフト(http://www.chemaxon.com/products/marvin/, version 5.7.0)に化合物構造を入力することで算出し,表に付記した。OCT3阻害剤をうつ病治療薬として利用する場合,脳内移行性が問題となる。既存のOCT3阻害剤では,logP値が小さいものが多く,脳内移行性が悪い。そこで,logP値が大きな化合物を設計し,そのlogP値を,IC50値と共に併記した。なお本logP値を用いて脳内移行性を予測できる。
Modeling for Blood-Brain Barrier Permeability Predictions, Drug absorption studies,
2008, volume VII, 3, 510-556 に基づき,次式
log(Brain/Blood) = -0.0148 ×PSA +
0.152 × logP + 0.139
を用いて算出した。なお PSA は極性表面積を表し,上記Marvinソフトを用いて計算した。
2010,p35-42)。
KCl, 1.5mM NaH2PO4, 1.2mM MgCl2, 1.2mM CaCl2, pH7.4)に溶解したOCT3阻害剤を,既報(J. Chem. Neuroanat. 2000
20:375-87)の方法に基づき,浸透圧ポンプで持続的に第三脳室内に注入する。注入より1週間後にマウスを再度シリンダー内で300秒間遊泳させ,無動時間を測定する。なお陽性対照群では,抗うつ薬イミプラミンを生理食塩水に溶かした上で(終濃度4, 8, 16 mg/kgの3種類を準備),2回目の強制水泳試験開始の30分前に腹腔内に投与する(各濃度の薬物を陽性対照となる各群に各々投与)。また陰性対照群では,上記OCT3阻害剤の替りに生理緩衝液のみを,OCT3阻害剤投与群と同様の投与方法と実験スケジュールで,持続的に第三脳室内に注入し,強制水泳試験を行う。
Lett. 2005 Jul 1-8;382(1-2):195-200)での結果と同様の結果が予想される。すなわち,陰性対照ではうつ病様症状が惹起され,300秒間の遊泳中のほとんどで無動状態を呈し(無動時間の平均値が200秒程度),IC50濃度に対して十分量のOCT3阻害剤を持続注入(0.25μl/hr)したマウスではこの無動状態は有意に短縮することが期待される(無動時間の平均値が70秒程度)。また,低用量の抗うつ薬イミプラミン(4mg/kg)あるいは低用量のOCT3阻害剤を各々単独で投与(0.25μl/hr)した場合には,強制水泳試験での無動時間は陰性対照に比して差が見られない(両者共に無動時間の平均値が200秒程度)と予測されるが,両者を併用した場合は陰性対照に対して無動状態を有意に短縮させる,と期待できる(無動時間の平均値が100秒程度)。以上の結果が得られれば,OCT3阻害剤の抗うつ作用が確認され,またイミプラミンとの併用効果についても確認できる。
“OCT3阻害剤の投与により,自発運動活性が亢進し,見かけ上無動行動が抑制されている(抗うつ作用がない)”という可能性を排除するため,先行文献(Kitaichi. et al, Neurosci Lett. 2005 Jul 1-8;382(1-2):195-200)と同様にして,OCT3阻害剤の投与前後の自発運動活性を測定する。
20:375-87)に基づき,浸透圧ポンプで持続的に第三脳室内に注入する。別の一群は偽手術を行い,陰性対照としてOCT3阻害剤の替りに生理緩衝液を第三脳室内に注入する。注入1週間後のマウスをプラスチックケージ(30cm×35cm×17cm)に入れて,覚せい剤メタンフェタミン(1 mg/kg)の静脈内投与前後の自発運動量の測定を行う。自発運動量は壁面に取り付けられた赤外線センサー(有限会社メルクエスト, SCANET SV-10)により,自動カウントする。覚せい剤メタンフェタミンの投与120分前から投与直前までは,陰性対照群における自発運動量およびOCT3阻害剤投与群の自発運動量を測定し,メタンフェタミンの投与直後から投与180分後までは,各群における覚せい剤誘発性自発運動量を測定する。測定後,各群の自発運動量のカウント数について,Scheffe法を用いた有意差検定を行い,自発運動量が統計的に有意(p値が0.05未満)に変化しているかどうかを判断する。
Lett. 2005 Jul 1-8;382(1-2):195-200)での結果と同様の結果が予想される。すなわち,覚せい剤メタンフェタミンの投与前では,陰性対照群及びOCT3阻害剤投与群において,共に同程度のカウント数の自発運動であり,覚せい剤メタンフェタミンの投与後は,OCT3阻害剤非投与群が陰性対照群の2倍程度のカウント数に,OCT3阻害剤投与群では陰性対照群の5倍程度のカウント数に,増加すると予測される。そしてカウント数を有意差検定することにより,覚せい剤メタンフェタミンの投与前における,陰性対照群とOCT3阻害剤投与群において有意差が無いこと,すなわちOCT3阻害剤の投与により自発運動量が変化しないことを確認できると期待できる。また覚せい剤メタンフェタミンの投与後は,投与前に比べ,統計的に有意に自発運動が亢進すると期待されることから,本試験系が有効に機能していることを確認できると期待できる。以上の結果が得られれば,OCT3阻害剤に自発運動活性がないことを確認でき,強制水泳試験によって確認された無動時間の短縮は,抗うつ作用を示す根拠となる。
Claims (10)
- 下記式(I)
R1~R3及びR5~R6は,同一でも異なってもよく,
水素原子,ハロゲン原子,C1-3アルキル基,C1-3アルコキシ基,C1-3アルキルチオ基,又はC1-3ハロゲノアルキル基を示し,
R4は,式(II)~式(VII)のいずれかの基を示し,
X2は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基,置換基を有しても良いC2-10アルキニル基,置換基を有しても良いC6-10アリール基,又は置換基を有してもよい良いC7-10アラルキル基を示し,
式(III)中,
X3は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,又は置換基を有しても良いC2-10アルキニル基を示し,
式(VI)中,
X4は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルキニル基,又は置換基を有しても良いC6-12アリール基を示し,
式(V)中,
X5は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルキニル基,置換基を有してよい5員環の基又は置換基を有しても良いC6-12アリール基を示し,
式(VI)中,
X6は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルキニル基,置換基を有してよい5員環の基又は置換基を有しても良いC6-12アリール基を示し,
式(VII)中,
X7は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルキニル基,置換基を有してよい5員環の基又は置換基を有しても良いC6-12アリール基を示す。)
で表される化合物,それらの薬学的に許容される塩,又はそれらの薬学的に許容される溶媒和物を有効成分として含む,
有機カチオントランスポーター3(OCT3)の阻害剤。
- 請求項1に記載の有機カチオントランスポーター3(OCT3)の阻害剤であって,
R1,R2,R3,R5及びR6は,それぞれ同一でも異なってもよく,水素原子又はメチル基を示し,
R4は,式(II)で示される基を示し,
式(II)中,
X2は,-Y21-Y22-Y23,又は-Y21-Y22(-Y23Y24)で示される基を示し,
Y21は,直鎖又は分岐のC1-5アルレン基を示し,
Y22は,単結合,酸素原子,硫黄原子,又はSO2で示される基を示し,
Y23及びY24は,同一でも異なってもよく,
水素原子;
C1-5アルキル基,
C3-6シクロアルキル基;
メチル基,=Oで示される基(カルボニル基)又はハロゲン原子で置換されても良い,ピロリジニル(pyrrolidinyl)基;
メチル基,=Oで示される基(カルボニル基)又はハロゲン原子で置換されても良い,チアゾリジニル(thiazolidinyl)基;
直鎖又は分岐のC1-5アルキル基に接続されたフェニル基;
直鎖又は分岐のC1-5アルキル基に接続されたC1-5アルコキシ基で置換されたフェニル基;
ハロゲン原子,ニトロ基,C1-5アルキル基,C1-5アルコキシ基,C1-5ハルゲノアルキル基,C1-5ハルゲノアルコキシ基,ピロリジニル(pyrrolidinyl)基,=Oで示される基(カルボニル基)で置換されたピロリジニル(pyrrolidinyl)基;又は
ベンゾイミダゾリル(benzomidazolyl)基;
を示すか,
X2は,-Y25(Y26)-Y27で示される基を示し,
Y25は,
ハロゲン原子,ニトロ基,C1-5アルキル基,C1-5アルコキシ基,C1-5ハルゲノアルキル基,C1-5ハルゲノアルコキシ基,ピロリジニル(pyrrolidinyl)基,=Oで示される基で1~3個の水素原子が置換されても良いフェニル基を示す。
Y26は,水素原子,フェニル基,C3-5シクロアルキル基,C1-5アルキル基で置換されても良いピロリジニル基,又はC1-5アルキル基で置換されても良いピロール基を示す。
Y27は,
水素原子;
ハロゲン原子;
C3-5シクロアルキル基,
直鎖又は分岐のC1-5アルキル基に接続されたピロリジニル(pyrrolidinyl)基;
直鎖又は分岐のC1-5アルキル基に接続されたピペリジニル(piperidinyl)基;
ジオキソラニル(dioxolanyl)基;
イミダゾリル(midazolyl)基;
-C(=O)-CH3で示される基;
-C(=O)-NH2で示される基;
-C(=O)-NC5H10で示される基;
-S(O2)NHCH3で示される基;
-S(O2)NHC3H7で示される基;
-NC(=O)OCH3で示される基;
-NC(=O)C3H5で示される基;
-NC(=O)C3H7で示される基;又は
を示す有機カチオントランスポーター3(OCT3)の阻害剤。 - 請求項1に記載の有機カチオントランスポーター3(OCT3)の阻害剤を有効成分として含むうつ病及びうつ様症状の治療剤であって,前記うつ病及びうつ様症状は,身体的抑うつ, 単極性うつ,心因性機能的疾患,非定形うつ,気分変調症,双極性感情病,季節性うつ,持続性気分障害を含むうつ病及びうつ様症状の治療剤。
- 下記式(I)
R1~R3及びR5~R6は,同一でも異なってもよく,
水素原子,ハロゲン原子,1~3アルキル基,1~3アルコキシ基,1~3アルキルチオ基,又は1~3ハロゲノアルキル基を示し,
R4は,式(II)~式(VII)のいずれかの基を示し,
X2は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルケニル基,置換基を有しても良いC2-10アルキニル基,置換基を有しても良いC6-10アリール基,又は置換基を有してもよい良いC7-10アラルキル基を示し,
X3は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,又は置換基を有しても良いC2-10アルキニル基を示し,
X4は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルキニル基,又は置換基を有しても良いC6-12アリール基を示し,
X5は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルキニル基,置換基を有してよい5員環の基又は置換基を有しても良いC6-12アリール基を示し,
X6は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルキニル基,置換基を有してよい5員環の基又は置換基を有しても良いC6-12アリール基を示し,
X7は,置換基を有しても良いC1-10アルキル基,置換基を有しても良いC1-10アルコキシ基,置換基を有しても良いC1-10アルキルチオ基,置換基を有しても良いC2-10アルキニル基,置換基を有してよい5員環の基又は置換基を有しても良いC6-12アリール基を示す。)
で表される化合物,それらの薬学的に許容される塩,又はそれらの薬学的に許容される溶媒和物を含む,
有機カチオントランスポーター3(OCT3)の検出剤。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/655,729 US20150329540A1 (en) | 2012-12-28 | 2013-12-17 | Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent |
EP13868302.4A EP2939675B1 (en) | 2012-12-28 | 2013-12-17 | Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent |
JP2014554340A JP6284490B2 (ja) | 2012-12-28 | 2013-12-17 | イミダゾピリジン誘導体を有効成分として含むoct3活性阻害剤又はoct3検出剤 |
US15/705,296 US10149840B2 (en) | 2012-12-28 | 2017-09-15 | OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-287682 | 2012-12-28 | ||
JP2012287682 | 2012-12-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/655,729 A-371-Of-International US20150329540A1 (en) | 2012-12-28 | 2013-12-17 | Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent |
US15/705,296 Division US10149840B2 (en) | 2012-12-28 | 2017-09-15 | OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014103801A1 true WO2014103801A1 (ja) | 2014-07-03 |
Family
ID=51020888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/083759 WO2014103801A1 (ja) | 2012-12-28 | 2013-12-17 | イミダゾピリジン誘導体を有効成分として含むoct3活性阻害剤又はoct3検出剤 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20150329540A1 (ja) |
EP (1) | EP2939675B1 (ja) |
JP (1) | JP6284490B2 (ja) |
WO (1) | WO2014103801A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019180686A1 (en) * | 2018-03-23 | 2019-09-26 | Cmg Pharmaceutical Co., Ltd. | Ido-tdo dual inhibitor and related methods of use |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0664060B2 (ja) | 1986-07-19 | 1994-08-22 | ベ−リンガ−・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 分析物の検出法及び検出剤 |
WO2001093863A2 (en) | 2000-06-06 | 2001-12-13 | Richter Gedeon Vegyészeti Gyár Rt. | Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression |
US6403645B2 (en) | 2000-03-16 | 2002-06-11 | President And Fellows Of Harvard College | Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them |
WO2005084707A1 (ja) | 2004-03-09 | 2005-09-15 | Biostation Inc. | うつ病、不安神経症、薬物依存症、およびこれらに類似した精神疾患治療のための有機カチオントランスポーターoct3関連分子の利用法 |
WO2009134877A2 (en) | 2008-04-29 | 2009-11-05 | Board Of Regents, The University Of Texas System | Therapeutics for treatment resistant mental disorders |
JP2009541473A (ja) * | 2006-07-03 | 2009-11-26 | サノフイ−アベンテイス | 治療剤におけるイミダゾ[1,2−a]ピリジン−2−カルボキサミド誘導体の使用 |
JP2011509251A (ja) * | 2008-01-02 | 2011-03-24 | サノフイ−アベンテイス | N−フェニル−イミダゾ[1,2−a]ピリジン−2−カルボキサミド化合物、この調製およびこの治療的用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006015737A1 (de) * | 2004-08-02 | 2006-02-16 | Schwarz Pharma Ag | Carboxamide des indolizins und seiner aza- und diazaderivate |
FR2903107B1 (fr) * | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
WO2008029152A2 (en) * | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
TW200831498A (en) * | 2006-10-13 | 2008-08-01 | Otsuka Pharma Co Ltd | Heterocyclic compound |
AU2008287421A1 (en) * | 2007-08-10 | 2009-02-19 | Glaxosmithkline Llc | Nitrogen containing bicyclic chemical entities for treating viral infections |
FR2925901B1 (fr) * | 2008-01-02 | 2011-03-04 | Sanofi Aventis | DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
US8133897B2 (en) * | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
AU2010255552A1 (en) * | 2009-06-05 | 2012-01-12 | Oslo University Hospital Hf | Azole derivatives as Wtn pathway inhibitors |
US8697911B2 (en) * | 2010-07-07 | 2014-04-15 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
DK2835131T3 (en) * | 2010-12-14 | 2017-12-04 | Electrophoretics Ltd | Casein kinase 1 delta inhibitors (CK1 delta) |
-
2013
- 2013-12-17 WO PCT/JP2013/083759 patent/WO2014103801A1/ja active Application Filing
- 2013-12-17 EP EP13868302.4A patent/EP2939675B1/en active Active
- 2013-12-17 JP JP2014554340A patent/JP6284490B2/ja active Active
- 2013-12-17 US US14/655,729 patent/US20150329540A1/en not_active Abandoned
-
2017
- 2017-09-15 US US15/705,296 patent/US10149840B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0664060B2 (ja) | 1986-07-19 | 1994-08-22 | ベ−リンガ−・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 分析物の検出法及び検出剤 |
US6403645B2 (en) | 2000-03-16 | 2002-06-11 | President And Fellows Of Harvard College | Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them |
WO2001093863A2 (en) | 2000-06-06 | 2001-12-13 | Richter Gedeon Vegyészeti Gyár Rt. | Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression |
WO2005084707A1 (ja) | 2004-03-09 | 2005-09-15 | Biostation Inc. | うつ病、不安神経症、薬物依存症、およびこれらに類似した精神疾患治療のための有機カチオントランスポーターoct3関連分子の利用法 |
US20070136828A1 (en) | 2004-03-09 | 2007-06-14 | Biostation Inc. | Methods of using molecules related to organic cation transporter 3 (oct3) for treating depression, anxiety neuroses, drug dependencies, and other similar mental disorders |
JP2009541473A (ja) * | 2006-07-03 | 2009-11-26 | サノフイ−アベンテイス | 治療剤におけるイミダゾ[1,2−a]ピリジン−2−カルボキサミド誘導体の使用 |
JP2011509251A (ja) * | 2008-01-02 | 2011-03-24 | サノフイ−アベンテイス | N−フェニル−イミダゾ[1,2−a]ピリジン−2−カルボキサミド化合物、この調製およびこの治療的用途 |
WO2009134877A2 (en) | 2008-04-29 | 2009-11-05 | Board Of Regents, The University Of Texas System | Therapeutics for treatment resistant mental disorders |
Non-Patent Citations (13)
Title |
---|
"Remington's Pharmaceutical Sciences, 17th ed.,", 1985, MACK PUBLISHING COMPANY, pages: 1418 |
BR J PHARMACOL., vol. 136, no. 6, 2002, pages 829 - 836 |
HAO-JIE ZHU ET AL.: "Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action", PHARMACOL RES., vol. 5, no. 4, pages 491 - 6, XP055268293 * |
J BIOL CHEM., vol. 193, no. 1, 1951, pages 265 - 75 |
J. CHEM. NEUROANAT., vol. 20, 2000, pages 375 - 87 |
KITAICHI ET AL., NEUROSCI LETT., vol. 382, no. 1-2, 1 July 2005 (2005-07-01), pages 195 - 200 |
KITAICHI. ET AL., NEUROSCI LETT., vol. 382, no. 1-2, 1 July 2005 (2005-07-01), pages 195 - 200 |
MINORU TSUJI ET AL., JAPANESE PHARMACOLOGICAL MAGAZINE, vol. 130, 2007, pages 97 - 104 |
NIES, HANDB EXP PHARMACOL., vol. 201, 2011, pages 105 - 167 |
PORSOLT RD, ARCH INT PHARMACODYN, vol. 229, 1977, pages 327 - 336 |
PRABHA ET AL.: "In Silico Modeling for Blood-Brain Barrier Permeability Predictions", DRUG ABSORPTION STUDIES, vol. VII, no. 3, 2008, pages 510 - 556 |
SATA, J PHARMACOL EXP THER., vol. 315, 2005, pages 888 - 895 |
YUTAKA NAKAGAWA: "practice behavioral pharmacology", KINPODO, 2010, pages 35 - 42 |
Also Published As
Publication number | Publication date |
---|---|
US20180000797A1 (en) | 2018-01-04 |
US20150329540A1 (en) | 2015-11-19 |
JPWO2014103801A1 (ja) | 2017-01-12 |
EP2939675B1 (en) | 2019-09-04 |
JP6284490B2 (ja) | 2018-02-28 |
EP2939675A1 (en) | 2015-11-04 |
EP2939675A4 (en) | 2016-09-14 |
US10149840B2 (en) | 2018-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Winchester et al. | Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans | |
Lamming | Inhibition of the mechanistic target of rapamycin (mTOR)–rapamycin and beyond | |
JP6991993B2 (ja) | 痛覚過敏を治療する方法 | |
TW524692B (en) | 5HT1 receptor agonists and metoclopramide for the treatment of migraine | |
US20190284196A1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
US11312721B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
CN107406438A (zh) | 溴结构域的抑制剂 | |
JP2007536241A (ja) | 糖尿病性腎症の処置のためのa2aアデノシンレセプターアゴニスト | |
AU2017216429A1 (en) | Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH) | |
JP2019503351A (ja) | オピオイド受容体リガンドおよびシトクロムp450阻害剤の組合せ | |
Masyuk et al. | Polycystic liver disease: advances in understanding and treatment | |
CN111432818A (zh) | 用于治疗神经精神性系统性红斑狼疮的吡唑并哌啶衍生物和吡唑并嘧啶衍生物 | |
CN109415342A (zh) | 用于治疗纤维化的wnt抑制剂 | |
JP6959371B2 (ja) | 純粋な5−ht6受容体アンタゴニストの新たな使用 | |
JP6284490B2 (ja) | イミダゾピリジン誘導体を有効成分として含むoct3活性阻害剤又はoct3検出剤 | |
JP6606298B2 (ja) | 純粋な5−ht6受容体アンタゴニストのnmda受容体アンタゴニストとの組合せ | |
US20210169882A1 (en) | Pharmaceutical composition for protecting or mitigating radiation damage, and for preventing or treating pulmonary fibrosis | |
KR102033699B1 (ko) | 치료 방법 | |
Chekol et al. | Carbon-11 and fluorine-18 radiolabeled pyridopyrazinone derivatives for positron emission tomography (PET) imaging of phosphodiesterase-5 (PDE5) | |
EP3965769B1 (en) | Use of 2-phenyl-6-(1h-imidazol-1-yl)quinazoline for treating neurodegenerative diseases, preferably alzheimer's disease | |
EP3833354B1 (en) | Tissue transglutaminase modulators for medicinal use | |
EP4073037A1 (en) | Small molecule inhibitors of voltage-gated sodium channel 1.7 and methods of using same | |
CN111432814A (zh) | 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途 | |
Kolik et al. | Experimental Evaluation of Anxiolytic and Analgesic Properties of a New Linear Methoxyphenyltriazaalkane Derivative with Cardiotropic Activity | |
US20230149357A1 (en) | Therapeutic agent for non-motor symptoms associated with parkinson's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13868302 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014554340 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14655729 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013868302 Country of ref document: EP |